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Abstract
RIPK3 was reported to play an important role in the protection against influenza A virus (IAV) in vivo. Here we show
that the requirement of RIPK3 for protection against IAV infection in vivo is only apparent within a limited dose range
of IAV challenge. We found that this protective outcome is independent from RIPK3 kinase activity and from MLKL. This
shows that platform function of RIPK3 rather than its kinase activity is required for protection, suggesting that a RIPK3
function independent of necroptosis is implicated. In line with this finding, we show that FADD-dependent apoptosis
has a crucial additional effect in protection against IAV infection. Altogether, we show that RIPK3 contributes to
protection against IAV in a narrow challenge dose range by a mechanism that is independent of its kinase activity and
its capacity to induce necroptosis.
Introduction
Influenza A viruses (IAVs) are negative-stranded RNA
viruses that belong to the Orthomyxoviridae family. IAVs
can cause influenza in birds and some mammals,
including humans. In mammals, IAV typically infects lung
epithelial cells and replicates in the nucleus where the
virus also hijacks the host’s transcription machinery1.
Programmed cell death (PCD) plays a role as a cell-
autonomous defense mechanism by which infected cells
die resulting in limited viral replication and spreading2.
Apoptosis is the major type of PCD upon in vitro infec-
tion of cells with IAV3,4, but necroptosis and pyroptosis
were also shown to be elicited5–9. Many viruses have
evolved genes that can block apoptosis such as viral
inhibitor of caspase-8 activation (vICA) and viral
mitochondria-localized inhibitor of apoptosis (vMIA) in
mouse cytomegalovirus (MCMV)10. These viral proteins
allow viruses to escape PCD. From an evolutionary point
of view necroptosis is an alternative cell death mechanism
that promotes the killing of host cells that acquired
resistance to caspase-8-mediated cell-extrinsic apoptosis
and can also restrict pathogen replication11. Receptor-
interacting serine/threonine-protein kinase 3 (RIPK3) is
activated by RIP Homology Interaction Motif (RHIM)-
dependent recruitment to RIPK1, TIR-domain-containing
adapter-inducing interferon-β (TRIF) or Z-nucleic acid
Binding Protein-1 (ZBP1)10,12. This results in RIPK3
autophosphorylation and phosphorylation of its substrate
mixed lineage kinase domain-like pseudokinase
(MLKL)13,14 which destabilizes the plasma membrane and
executes necroptosis15,16.
RIPK3 was reported to be crucial for the protection
against IAV. Some studies report that Ripk3−/− mice are
more susceptible to IAV infection suggesting the impor-
tance of this protein in the in vivo protection against IAV
infection5,7,17. During IAV replication virally-derived
RNA molecules are sensed by ZBP1, which binds to
RIPK3 to initiate parallel cell modality outcomes of pyr-
optosis, apoptosis, and necroptosis within the population
of infected cells, collectively coined PANoptosis18. Intra-
cellular viral replication also activates RIPK3 to drive
PCD19. In vitro, RIPK3 was shown to activate in parallel
© The Author(s) 2021
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Peter Vandenabeele (Peter.Vandenabeele@irc.vib-ugent.be)
1VIB-UGent Center for Inflammation Research, Ghent, Belgium
2Department of Biomedical Molecular Biology, Ghent University, Ghent,
Belgium
Full list of author information is available at the end of the article
Edited by M Agostini


































both MLKL-mediated necroptosis and Fas-associated
protein with death domain (FADD)-induced apoptosis
in IAV infected cells7. It was also shown that replicating
IAV activates the RNA sensor ZBP1 in the nucleus, fol-
lowed by RIPK3 activation and nuclear MLKL phos-
phorylation resulting in nuclear envelope disruption, and
necroptosis20. However, the involvement of necroptosis in
IAV infection remains controversial in vivo. While some
studies report that RIPK3-mediated necroptosis may
negatively impact on survival by inducing immuno-
pathology21, others show that necroptosis does not affect
survival and that it functions as a protective backup
mechanism only when the proteolytic inactivity of
caspase-8 is compromised16,20. We hypothesized that
these apparent discrepancies in the susceptibility in terms
of survival between of Ripk3−/− mice to IAV infection
may be due to differences in the viral dose used to chal-
lenge the mice. Moreover, previous conclusions related to
the role of necroptosis in IAV infection through the use of
Ripk3−/− mice should be taken with caution as RIPK3 is
required to induce both apoptosis and necroptosis
downstream of ZBP16. While some studies suggest that
necroptosis ensures protection against IAV in murine12,21
others found that necroptosis is only functioning as a
backup mechanism when apoptosis is blocked5. Further-
more, in response to an IAV challenge dose that was
lethal for wild-type (WT) mice, a significant fraction of
the Mlkl/− mice survived this challenge dose20. These
discrepancies between studies that report increased sus-
ceptibility of RIPK3-deficient mice to IAV infection7,17,20
and those that described no change in susceptibility
between Ripk3−/− mice and WT controls21, may be due to
differences in the viral dose used to challenge the mice.
Here, we investigated the susceptibility of RIPK3-deficient
mice to a range of viral doses and examined the possible
involvement of either RIPK3-induced necroptosis or
apoptosis. Our results confirm that RIPK3 is implicated in
a protective response during viral infection but only at a
limited range of IAV challenge doses. Moreover, we
demonstrate that the protective effect is independent of
RIPK3 kinase activity and its downstream substrate
MLKL. We additionally show that FADD is crucial for
protection against limited IAV challenge doses. We
therefore propose that RIPK3 platform activity-dependent
and FADD-mediated apoptosis partially protect labora-
tory mice against IAV-infection in vivo.
Results
RIPK3-mediated protection is only observed at medium
dose of IAV infection in vivo
To assess the protective role of RIPK3 against IAV
challenge in vivo, we challenged WT littermates and
RIPK3-deficient mice with different doses of PR8 virus, a
commonly used human-origin laboratory strain of IAV.
We exposed the mice to different infection doses: very low
IAV dose (0.05x LD50 or 4 pfu), low dose (0.1x LD50 or 8
pfu), medium IAV dose (0.2x LD50 or 16 pfu) and high
IAV dose (0.5x LD50 or 40 pfu). Following a very low
challenge dose (0.05x LD50/4 pfu), Ripk3
−/− and WT mice
displayed similar mortality and most of the mice survived
the challenge (as defined in Materials and Methods) (Fig.
1a, b). Doubling the challenge dose from 0.05x LD50/4 pfu
to 0.1x LD50/8 pfu revealed a tendency towards increased
sensitivity of RIPK3-deficient mice, though not statistically
significant. For the medium viral dose of infection (0.2x
LD50/16 pfu) the susceptibility of Ripk3
−/− mice is sig-
nificantly potentiated (p value= 0.0218) compared to
Ripk3+/+ littermates. Infection with high viral dose (0.5x
LD50/40 pfu) leads to 100% lethality in both Ripk3
−/− mice
and Ripk3+/+ littermates (Fig. 1d). Altogether, these
results suggest that, in contrast to many studies that report
only one dose of viral infection, the involvement of RIPK3
for protection against IAV infection is partial and can only
be demonstrated within a narrow dose-range, which is in
our case the medium dose of 0.2x LD50/16 pfu. For this
dose, the surviving Ripk3−/− mice seem to suffer slightly
more weight loss compared to WT controls. This is most
probably due to slower recovery of the RIPK3-deficient
mice and not due to enhanced morbidity during the first
9–10 days of infection. We do not observe any shift in the
bodyweight loss curve for the other infection doses sug-
gesting that RIPK3 only affects the mortality threshold (i.e.
the ethical endpoint) of the mice (Fig. 1).
MLKL does not protect against different IAV challenge
doses in vivo
In view of the reported protective role of the RIPK3-
MLKL axis against IAV infection of cells in vitro7 and
because of the protective role of RIPK3 in vivo at certain
infection doses of IAV (Fig. 1), we wanted to clarify
whether RIPK3 acted through activation of MLKL during
in vivo IAV infection. Therefore, we challenged MLKL-
deficient mice and their littermate controls with low (0.1x
LD50/ 8 pfu) medium (0.2x LD50/16 pfu) and high IAV
doses (0.5x LD50/40 pfu). Survival analysis and bodyweight
loss curves are shown in Fig. 2a–c. Mlkl+/+ and MLKL-
deficient mice displayed the same bodyweight loss and
survival at any of the challenge doses used, excluding a
role for MLKL downstream of RIPK3 during protection
against medium-dose IAV infection. This confirms pre-
viously published results where deficiency of MLKL alone
did not affect the lethal sensitivity during IAV infection5,16.
RIPK3 platform function but not its kinase activity is
required for protection against medium IAV infection dose
in vivo
To examine if the kinase activity of RIPK3 is important
for the protection against IAV, we infected with different
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Fig. 1 RIPK3 is partially required for protection at medium IAV dose in vivo. Survival analysis and body weight loss of age-matched Ripk3−/−
and Ripk3+/+ mice infected intranasally with IAV is shown at very low dose: 0.05x LD50/4 pfu; (a), low dose: 0.1x LD50/8 pfu p value = 0.3340 (b),
medium dose: 0.2x LD50/16 pfu p value= 0.0218 (c) and high dose: 0.5x LD50/40 pfu (d). Data were pooled from 2 (panel A and B) or 3 (c, d)
independent experiments. Bodyweight curves are shown as mean ± SD. Survival curves were plotted for indicated groups and evaluated statistically
according to Kaplan–Meier. A log-rank test verified significant differences between Ripk3+/+ and Ripk3−/− mice (GraphPad Prism 7). *p < 0.05.
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IAV doses (low, medium, high, as defined above) mice
that lack the kinase activity of RIPK3, i.e. RIPK3K51A
knock in mice. The bodyweight loss and lethality of Ripk3
KD-KIK51A/K51A mice infected with low (0.1x LD50/8 pfu),
medium (0.2x LD50/16 pfu), and high viral dose (0.5x
LD50/40 pfu) are not statistically significantly different
from their littermates, the Ripk3 KD-KI+/+ (Fig. 3a–c).
This suggests that that the kinase activity of RIPK3
apparently is not required for the protective effect during
IAV infection. This observation is in line with the absence
of a sensitizing phenotype in Mlkl−/− mice following IAV
infection (Fig. 2a–c). Altogether our findings favor a
model in which the platform function of RIPK3 rather
than its RIPK3 kinase activity and consecutive MLKL-
mediated necroptosis is implicated in the protective effect
against the medium dose IAV infection in vivo.
FADD is required for RIPK3-mediated protection against
low and medium IAV doses in vivo
RIPK3 can function as a platform that stimulates apop-
tosis22. Since Fadd−/−mice die in utero23 due to excessive
RIPK3/MLKL-mediated necroptosis in multiple tissues24,
we infected Ripk3−/−Fadd−/− double knock out (DKO)
mice with low (0.1x LD50/8 pfu), medium (0.2x LD50/16
pfu), and high viral dose (0.5x LD50/40 pfu) of IAV infection
to study the possible contribution of the FADD-caspase-8
Fig. 2 MLKL is not required for partial protection against IAV infection at different viral doses. Survival analysis and bodyweight loss of age-
matched Mlkl−/− and Mlkl+/+ infected intranasally with IAV is shown at each infection: low dose: 0.1x LD50/8 pfu (a), medium dose: 0.2x LD50/16 pfu
(b) and high dose: 0.5x LD50/40 pfu (c). Data were pooled from 2 (a, c) or 3 (b) independent experiments. Bodyweight curves are shown as mean ±
SD. Survival curves were plotted for indicated groups and evaluated statistically according to Kaplan–Meier (GraphPad Prism 7). NS not significant.
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apoptotic axis. These DKO mice are born at normal Men-
delian frequency and develop normally25. Their survival and
bodyweight loss were monitored up to 18 days post-IAV
infection (Fig. 4a–c). Interestingly, already at a low dose of
infection (0.1x LD50/8 pfu) Ripk3
−/−Fadd−/− DKO mice
showed enhanced susceptibility to IAV compared to their
littermates (p value= 0.0878) and compared to RIPK3-
deficient mice (p value =0.0066). All Ripk3−/−Fadd−/−
DKO mice died after the challenge, none of them being able
to recover from infection-induced morbidity compared to
the control mice (Fig. 4a–c). These results resemble the
previously reported phenotype of sensitization following
IAV infection of Fadd−/−Mlkl−/− DKO7 or the Casp8-
DAMlkl−/− mice5. This suggests the importance of
FADD-dependent apoptosis in the protection against IAV
infection. Moreover, the susceptibility of Ripk3−/− Fadd−/−
double knock-out mice is further increased compared to
RIPK3-deficient mice for the same doses, suggesting that
residual RIPK3-independent and FADD-dependent apop-
tosis mediates protection against IAV independent from
RIPK3 or MLKL (Fig. 4a).
Discussion
Several reports have highlighted the role of RIPK3 in the
protection against IAV infection5,7,17,21. Furthermore, it was
shown that genetic deletion of ripk3 rescued cellular inhi-
bitor of apoptosis 2 (cIAP2)-deficient mice from influenza-
induced lethality via RIPK3-mediated necroptosis21.
Fig. 3 RIPK3 kinase activity is not required for partial protection against IAV infection at different viral doses. Survival analysis and
bodyweight loss of age-matched Ripk3 KD-KIK51A/K51A and Ripk3 KD-KI+/+ mice infected intranasally with IAV is shown at each infection dose: low
dose: 0.1x LD50/8 pfu, (a), medium dose: 0.2x LD50/16 pfu, (b) and high dose: 0.5x LD50/40 pfu (c). Data were pooled from 2 (panel A), 3 (c) or 5 (b)
independent experiments. Bodyweight curves are shown as mean ± SD. Survival curves were plotted for indicated groups and evaluated statistically
according to Kaplan–Meier (GraphPad Prism 7). NS not significant.
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In contrast, it has also been reported that infection with a
sublethal IAV dose resulted in similar susceptibility of
RIPK3-deficient mice as WT mice21, suggesting that the
in vivo protective role of RIPK3 against IAV challenge
infection may be dose dependent. This absence of pheno-
type of RIPK3-deficient mice is comparable to what we
observe when mice are infected with a very low and low IAV
dose. This observation is in contrast with other studies that
reported that RIPK3-deficient mice were highly susceptible
to a sublethal viral (50 pfu) dose as well as to a lethal dose
(90 pfu, 1x LD50) of IAV, including the PR8 virus strain that
we used here7,17. Therefore, the opposing conclusions in the
literature with regard to the protective role of RIPK3 fol-
lowing IAV challenge might be very likely explained by
discrepancies in doses of IAV challenge leading to between
reports emphasizing its protective role7 or those dismissing a
Fig. 4 FADD is required against low and medium IAV doses in vivo. Survival analysis and bodyweight loss of age-matched Ripk3−/−Fadd−/−
DKO and WT controls Ripk3+/+ Fadd+/+ as well as single Ripk3−/− and Ripk3+/+ mice infected intranasally with PR8 are shown: low dose: 0.1x LD50/8
pfu (a), medium dose: 0.2x LD50/16 pfu (b) and high dose: 0.5x LD50/40 pfu (c). Data were pooled from 2 (a) or 3 independent experiments (b, c).
Bodyweight curves are shown as mean ± SD. Survival curves were plotted for indicated groups and evaluated statistically according to Kaplan–Meier
(GraphPad Prism 7). NS not significant; *p < 0.05, **p < 0.01, and ***p < 0.001.
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role for RIPK317. Importantly, in our study we reconcile
these observations by demonstrating that depending on the
challenge dose range, RIPK3 can contribute or not to pro-
tection against IAV infection in vivo.
Next, we addressed whether the role of RIPK3 in
partial IAV protection could be attributed to RIPK3-
mediated MLKL phosphorylation and necroptosis
execution. MLKL-deficient mice challenged with dif-
ferent IAV infection doses (low, medium, and high) did
not exhibit increased susceptibility compared to WT
littermates suggesting that necroptosis execution
mechanism apparently is not implicated in IAV pro-
tection in vivo, confirming previously published
data7,20. This result prompted the question whether the
RIPK3 kinase activity would be implicated or not in the
in vivo protection. To this end, we challenged RIPK3
kinase activity deficient Ripk3 KD-KIK51A/K51A mice
with different IAV doses. These mice responded like
control littermates excluding the RIPK3 kinase invol-
vement in the protective process to IAV in murine
hosts. We noticed that not all littermate controls
respond equally to the viral challenge. For instance, the
Ripk3 KD-KI+/+ and the Mlkl +/+ mice are more sus-
ceptible than Ripk3+/+ for the same viral challenge dose
(0.2x LD50). The use of littermate controls is essential
when comparing the outcome of an immunity-related
stimulus between genetically modified strains26,27.
Particularly when evaluating viral susceptibility of KO
mice, specific littermate controls should be used in each
experiment. The Kaplan-Meier survival curves of all the
wild-type control littermates for every knockout line
used in this study is shown in Supplementary Fig. 1.
When we put all results of wild-type littermates with
wild-type alleles in one figure, we noticed significant
variation in survival following infection with the high
dose (0.5x LD50/40 pfu). This illustrates genetic and
experimental differences over the years between control
littermates with wild-type alleles, reinforcing the point
that conclusions can only be drawn using the appro-
priate littermates. In all figures, we pooled data from
mutant mice with appropriate wild type littermate
controls each time performed in the same experimental
setup as indicated in the figure legends.
Besides necroptosis, RIPK3 has also been reported to
induce NF-kB activation upon overexpression28, is
involved in cytokine production29, can promote acti-
vation of apoptosis as a kinase-dead platform22,30 and is
implicated in NLR family pyrin domain containing 3
(NLRP3) inflammasome activation in response to
polyinosinic:polycytidylic acid [poly(I:C)] and lipopo-
lysaccharides22,31–33 and RNA viruses34. The role in
NF-kB activation has been controversial, since experi-
ments based on cells from Ripk3−/− revealed that
RIPK3 is dispensable for normal NF-κB, signaling by
the B-Cell and T-Cell Receptors, tumor necrosis factor
receptor 1 (TNFR1), and toll-like receptor (TLR) 2 and
TLR428. RIPK3 was shown to activate the NLRP3
inflammasome in IAV infected cells6. Depending on the
biological context, RIPK3 was shown to be dispensable
for inflammasome activation by RNA viruses35 or
required for the NLRP3 inflammasome induced by LPS
in which case the kinase activity is required as it can be
inhibited by the RIPK3 kinase inhibitor GSK87236.
Inflammasome activation is described to be involved in
the protection against a wide variety of viruses such as
IAV, herpes simplex virus 1 (HSV-1), West Nile virus
(WNV), Sendai virus, respiratory syncytial virus (RSV),
encephalomyocarditis virus (EMCV). However, two
independent studies showed that mice lacking compo-
nents of the NLRP3 inflammasome pathway, such as
Caspase-1/11 DKO mice and Nlrp3 KO mice infected
with a sublethal IAV dose did not exhibit increased
susceptibility compared to their WT littermates sug-
gesting that these pathways apparently are not crucial
for protection in this context21,37.
As mentioned above, the platform function of RIPK3 is
implicated in the induction of apoptosis through the
recruitment of RIPK1, FADD, and caspase-822,38. In order
to examine this apoptosis-connected platform function of
RIPK3, we challenged Ripk3−/− Fadd−/− DKO mice to
assess susceptibility to IAV infection. Our results reveal
that even a low viral infection dose is sufficient to kill all
Ripk3−/−Fadd−/− DKO mice shortly after infection even
to a higher extend than Ripk3−/− mice, showing indi-
cating that FADD-mediated apoptosis is implicated. This
strong sensitization of IAV-mediated lethality in the
absence of both FADD and RIPK3 (this paper) or both
FADD and MLKL7, or both caspase 8 protease activity
and MLKL5 all argue for the crucial involvement of
apoptosis rather than necroptosis in controlling the life
or death outcome following IAV infection. Moreover,
since the absence of both FADD and RIPK3 sensitizes to
lethality following IAV infection even more than loss of
RIPK3 kinase activity, a paradigm emerges in which
beyond RIPK3 platform-mediated apoptosis also other
apoptotic pathways are probably implicated with even
higher protective potential. Although we do not show any
mechanistical connection between FADD and RIPK3, our
results show that in addition to the RIPK3-mediated
protection, FADD exerts an additional protective effect.
Furthermore, it was described that cytotoxic CD8+
T cells induce Fas-mediated apoptosis to destroy infected
cells of the lung epithelia. This process was shown to be
crucial for limiting in vivo viral pneumonia due to IAV
infection39. Also, caspase-8 is critical for proper TLR and
NF-κB involved in immune defense and its loss in B cells
is associated with a reduced anti-viral antibody
response40. Figure 5 summarizes a model on the
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involvement of FADD and RIPK3 in the protection
against limited doses of IAV infection. In IAV infection,
apoptosis is the primary host cell defense mechanism
inducing viral clearance and limiting viral spread41. A
previous study showed an increase in virus spread,
enhanced pulmonary edema, and alveolar damage in
influenza A virus-infected Ripk3−/− compared to WT
mice. Moreover, the RIPK3-deficient mice also had sig-
nificantly lower CD3+ and IAV-specific CD8+ T cells7.
In conclusion, we propose a paradigm by which RIPK3
platform-dependent and RIPK3-independent FADD-
mediated apoptosis are crucial for protection against IAV
in vivo, and that MLKL-mediated necroptosis is dis-
pensable at least when the activity of caspase-8 is not
compromised. Moreover, our results emphasize the
absolute need to examine sensitivity to different viral
doses in vivo in order to obtain a comprehensive view on
the role of cell death molecules in viral protection. Indeed,
often published statements are made based on the use of
one single infection dose in vivo possibly leading to
incomplete conclusions that only apply to particular IAV
infection doses. Moreover, the use of littermate controls is
the best good practice while working with mice contain-
ing mutated alleles. Even then, small phenotypic differ-
ences can occur between different littermate control mice
with wild type alleles due to passenger mutations27.
Material and methods
Mice
Ripk3−/− were kindly provided by Dr. Vishva Dixit
(Genentech, San Francisco)38, Mlkl−/− by Dr. Alexander
Warren and Dr. James Murphy42 and Ripk3 K51A kinase
dead knock-in (Ripk3 KD-KIK51A/K51A) mice by Dr. John
Bertin by GlaxoSmithKline22. The Ripk3−/− animals were
congenic to the C57BL/6 N background, while all other
strains were of the C57BL/6 J background, and were
therefore compared with the appropriate littermate con-
trols. Ripk3−/− mice were housed in individually venti-
lated cages in a conventional animal house. The other
mice were bred and housed in the SPF facility in indivi-
dually ventilated cages. Three weeks prior to the experi-
ment all mice were transferred to the conventional animal
house and allowed to go through a quarantine and
accommodation period of minimum 3 weeks before the
infection experiment. Littermate controls of Ripk3−/−,
Mlkl−/−, Ripk3−/−Fadd−/− and Ripk3 KD-KIK51A/K51A
were used in each experiment. In all experiments, 10–15-
week-old mice were used. All animal experiments were
done under conditions specified by law (European
Directive and Belgian Royal Decree of November 14,
1993) and approved by the Institutional Ethics Committee
on Experimental Animals.
Viral infection
Age-matched mice were anesthetized with a cocktail of
87,5 mg/kg ketamine and 12,5 mg/kg xylazine intraper-
itoneally and infected intranasally with 50 μl/20 g
phosphate-buffered saline (PBS) containing different
doses of influenza virus A/PR/8/3443, as described in the
legends. The plaque-forming units (pfu) were determined
by plaque assay on Madin-Darby Canine Kidney (MDCK)
cells, as described previously44. The LD50 of the viral
batch was determined on BALB/c mice and 1x LD50
represented 80 pfu, as determined in the lab of Prof.
Saelens. Although the LD50 is not referring to 50% of
death in the mice that were used in this study, the
nomenclature is used together with the pfu to have a
Supplementary information regarding the power of the
virus in vivo. This terminology is often used in the papers
cited here. Age- and sex-matched mice were challenged
Fig. 5 Graphic summary: involvement of FADD and RIPK3 in
protection at different doses of IAV challenge. After low to
medium IAV challenge dose in vivo, intracellular IAV activates FADD to
drive apoptosis of infected cells and protects the host (main pathway
involved in protection). RIPK3 is not essential to activate FADD-
dependent apoptosis post IAV infection. The platform function of
RIPK3 can associate with FADD and caspase-8 to drive apoptosis (to a
lesser extent than the main pathway which is RIPK3-independent) or
other cell death-independent mechanism for protection. The kinase
active RIPK3 and downstream MLKL are not involved in the protection
against IAV.
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with 0.05x LD50 (4 pfu), 0.1x LD50 (8 pfu), 0.2x LD50 (16
pfu) or 0.5x LD50 (40 pfu) and monitored for survival and
weight loss over a period of at least 18 days. We used the
following 4 scores of clinical symptoms: 0 = no visible
signs of disease; 1 = slight ruffling of fur; 2 = ruffled fur,
reduced mobility; 3 = ruffled fur, reduced mobility, rapid
breathing; 4 = ruffled fur, minimal mobility, huddled
appearance, rapid and/or labored breathing indicative of
pneumonia and body temperature below 32 °C. For the
combination of body weight loss by 30% and a clinical
score 4 the mice were considered moribund and eutha-
nized by CO2 asphyxiation or cervical dislocation
(EC2016–17).
Statistics
All the survival data were analyzed by Kaplan-Meier
survival analysis using the software Prism 7.04 (Graph-
Pad), and p‐values were calculated.
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